Extended duration dapivirine vaginal ring shows promise for HIV prevention
02 Apr 2021
byRoshini Claire Anthony
The use of a 90-day extended duration vaginal ring containing 100 or 200 mg of the antiretroviral drug dapivirine appeared safe, effective, and acceptable among HIV-negative women, according to results of a phase I trial presented at CROI 2021.
